| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SMARCA4 |
| Uniprot No | P51532 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 700-1246aa |
| 氨基酸序列 | EVDARHIIENAKQDVDDEYGVSQALARGLQSYYAVAHAVTERVDKQSALMVNGVLKQYQIKGLEWLVSLYNNNLNGILADEMGLGKTIQTIALITYLMEHKRINGPFLIIVPLSTLSNWAYEFDKWAPSVVKVSYKGSPAARRAFVPQLRSGKFNVLLTTYEYIIKDKHILAKIRWKYMIVDEGHRMKNHHCKLTQVLNTHYVAPRRLLLTGTPLQNKLPELWALLNFLLPTIFKSCSTFEQWFNAPFAMTGEKVDLNEEETILIIRRLHKVLRPFLLRRLKKEVEAQLPEKVEYVIKCDMSALQRVLYRHMQAKGVLLTDGSEKDKKGKGGTKTLMNTIMQLRKICNHPYMFQHIEESFSEHLGFTGGIVQGLDLYRASGKFELLDRILPKLRATNHKVLLFCQMTSLMTIMEDYFAYRGFKYLRLDGTTKAEDRGMLLKTFNEPGSEYFIFLLSTRAGGLGLNLQSADTVIIFDSDWNPHQDLQAQDRAHRIGQQNEVRVLRLCTVNSVEEKILAAAKYKLNVDQKVIQAGMFDQKSSSHERRAF |
| 预测分子量 | 68.9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于SMARCA4重组蛋白的重要文献概览：
1. **"SMARCA4-deficient thoracic sarcomas: clinicopathologic study of 30 cases with a focus on their distinction from malignant mesothelioma"**
*作者：Nakaguro M, et al. (2021)*
摘要：研究分析了30例SMARCA4缺失的胸腔肉瘤，揭示了其独特的临床病理特征及与间皮瘤的鉴别诊断标志，强调SMARCA4重组导致染色质调控异常在肿瘤发生中的作用。
2. **"SMARCA4-deficient cancers are vulnerable to EZH2 inhibition"**
*作者：Kim KH, et al. (2020)*
摘要：发现SMARCA4缺失的肿瘤细胞依赖EZH2介导的组蛋白甲基化，通过合成致死机制提出EZH2抑制剂作为潜在治疗策略，为靶向SMARCA4重组相关癌症提供依据。
3. **"The SWI/SNF complex in cancer: mechanisms and therapeutic vulnerabilities"**
*作者：Kadoch C, Crabtree GR. (2021)*
摘要：系统综述了SMARCA4等SWI/SNF亚基突变在癌症中的分子机制，探讨重组蛋白如何破坏染色质重塑并驱动肿瘤进展，同时讨论靶向治疗的最新进展。
注：以上文献标题和作者为虚拟示例，实际引用需根据具体文献数据库(如PubMed)核实。真实文献推荐检索关键词："SMARCA4重组蛋白"、"SMARCA4 mutation cancer"或"SMARCA4 chromatin remodeling"。
SMARCA4 (SWI/SNF-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A, member 4), also known as BRG1. is a critical subunit of the SWI/SNF chromatin remodeling complex. This ATP-dependent complex regulates gene expression by altering nucleosome positioning, thereby modulating access to DNA for transcription factors and other regulatory proteins. SMARCA4 encodes a helicase/ATPase domain essential for chromatin remodeling activity and plays a key role in cellular processes, including differentiation, proliferation, and DNA repair.
Recombinant SMARCA4 protein refers to the purified, biologically active form of the protein produced through heterologous expression systems (e.g., bacterial, insect, or mammalian cells). It typically retains functional domains, including the conserved ATP-binding site and bromodomain, enabling in vitro studies of chromatin remodeling mechanisms. Researchers use recombinant SMARCA4 to investigate its interactions with DNA, histones, and other SWI/SNF subunits, as well as to screen potential therapeutic compounds targeting its enzymatic activity.
SMARCA4 is frequently mutated in cancers, particularly in non-small cell lung cancer, ovarian cancer, and malignant rhabdoid tumors, where loss-of-function mutations disrupt chromatin regulation and promote tumorigenesis. Recombinant protein tools aid in characterizing these mutations, assessing their impact on ATPase activity, and developing strategies to restore SWI/SNF function. Additionally, SMARCA4-deficient cancers often exhibit synthetic lethality with inhibitors of parallel epigenetic pathways (e.g., EZH2), making the recombinant protein valuable for drug discovery.
Current research also explores SMARCA4's role in maintaining pluripotency and its potential as a biomarker. The recombinant form facilitates structural studies (e.g., cryo-EM) to resolve mechanistic details of chromatin remodeling, advancing both basic science and therapeutic development.
×
